Sign In
Last checked at 
14 Jan 2013 07:00
ο»Ώ
For immediate release | 14 January 2013 |
Β
Β
Futura Medical PLC
("Futura" or the "Company")
Β
Notification of Preliminary Results
Β
Futura Medical plc (AIM: FUM), the pharmaceutical group that develops innovative products for consumer healthcare, will announce its preliminary results for the year ended 31 December 2012 on Thursday 7 March 2013.
Β
A briefing for analysts will be held at 10.00am on the morning of the results at the offices of Buchanan, 107 Cheapside, London, EC2V 6DN.
Β
For more information, or to register attendance, please contact Buchanan on 020 7466 5000.
Β
Β
For further information:
Β
Futura Medical plc | + 44 (0) 1483 685 670 |
James Barder, Chief Executive Officer | |
Mail to: James.Barder@futuramedical.com | www.futuramedical.com |
Nomura Code Securities Limited | + 44 (0) 20 7776 1200 |
Phil Walker / Giles Balleny | |
Β | |
Buchanan | + 44 (0) 20 7466 5000 |
Mark Court / Fiona Henson / Sophie Cowles |
Β
Β
Notes to editors:
Β
About Futura Medical plc
Β
Futura Medical is a pharmaceutical group that develops innovative products for consumer healthcare. The Company is developing a portfolio of products and its strategy is to license their manufacture and distribution to major pharmaceutical and healthcare groups.
Β
Futura is based in Guildford, Surrey, and its shares trade on the AIM market of the London Stock Exchange.
Β
www.futuramedical.comΒ
Β
Β
Follow the stocks
